ASH: CRISPR-Cas9 Gene Editing Promising in TDT, SCD
THURSDAY, Dec. 10, 2020 (HealthDay News) — Use of the ex vivo CRISPR-Cas9-based gene-editing platform to edit the erythroid enhancer region of BCL11A in hematopoietic stem and progenitor cells, producing CTX001, results in...
Read More